{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.3","value":"51.7"},{"groupId":"OG001","spread":"40.1","value":"48.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"At baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.4","value":"32.1"},{"groupId":"OG001","spread":"32","value":"56.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"At off-treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"UW-QOL Global Question 1 assessed how participants felt relative to before they developed their cancer. The mean score was calculated among all participants who provided a response to this question. Responses were recorded on a 5-point ordinal scale and transformed to a 0-100 score, where 0 = Much worse, 25 = Somewhat worse, 50 = About the same, 75 = Somewhat better, and 100 = Much better.","dispersionType":"Standard Deviation","groups":[{"description":"Participants will receive:\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"OG000","title":"9-ING-41 + Carboplatin (Part I)"},{"description":"Participants will receive:\n\nPembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy).\n\n9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit.\n\nCarboplatin administered once per 21-day cycle on Day 1 for up to 1 year.","id":"OG001","title":"Pembrolizumab + 9-ING-41 + Carboplatin (Part II)"}],"paramType":"MEAN","populationDescription":"Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype. The number analyzed for each row reflects the number of participants who completed the question at the corresponding time point","reportingStatus":"POSTED","timeFrame":"Baseline and off-treatment (end-of-treatment) assessment; maximum treatment duration was 15.6 months.","title":"Mean Score of Global Question 1 in University of Washington Quality of Life Questionnaire (UW-QOL)","type":"SECONDARY","unitOfMeasure":"score on a scale"}